Who are Shinobi Therapeutics Inc.'s investors?

Shinobi Therapeutics Inc.'s investors include Astellas Venture Management LLC, F-Prime Capital, Fast Track Initiative, JIC Venture Growth Investments, Kyoto University Innovation Capital, EQT Life Sciences.

Shinobi Therapeutics Inc.

Founded 2023 · 38 employees on LinkedIn · 6 known investors

Find your way into Shinobi Therapeutics Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Shinobi Therapeutics Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.

AI & Machine Learning Biotech Healthtech Medical Devices

Investors · 6

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us

Fast Track Initiativelisted by Fast Track InitiativeTokyo

JIC Venture Growth Investmentslisted by JIC Venture Growth InvestmentsTokyo

How we know: JIC Venture Growth Investments's portfolio page · Not right? Tell us

Kyoto University Innovation Capitallisted by Kyoto University Innovation CapitalKyoto

How we know: Kyoto University Innovation Capital's portfolio page · Not right? Tell us

EQT Life SciencesreportedAmsterdam · $11M – $66M

How we know: a partner's Signal profile · Not right? Tell us

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Northwest BiotherapeuticsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.

Companies working in the same space as Shinobi Therapeutics Inc..

Frequently asked questions

What does Shinobi Therapeutics Inc. do?: Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
Who are Shinobi Therapeutics Inc.'s investors?: Shinobi Therapeutics Inc.'s investors include Astellas Venture Management LLC, F-Prime Capital, Fast Track Initiative, JIC Venture Growth Investments, Kyoto University Innovation Capital, EQT Life Sciences.